These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 10126753)

  • 1. Economic evaluation of osteoporosis prevention.
    Johannesson M; Jönsson B
    Health Policy; 1993 May; 24(2):103-24. PubMed ID: 10126753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic evaluation in health care: is there a role for cost-benefit analysis?
    Johannesson M; Jönsson B
    Health Policy; 1991 Feb; 17(1):1-23. PubMed ID: 10113574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using cost-effectiveness/cost-benefit analysis to allocate health resources: a level playing field for prevention?
    Phillips KA; Hotlgrave DR
    Am J Prev Med; 1997; 13(1):18-25. PubMed ID: 9037338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic evaluation of osteoporosis liaison service for secondary fracture prevention in postmenopausal osteoporosis patients with previous hip fracture in Japan.
    Moriwaki K; Noto S
    Osteoporos Int; 2017 Feb; 28(2):621-632. PubMed ID: 27699441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preliminary cost-effectiveness analysis of an AIDS vaccine in Abidjan, Ivory Coast.
    Cowley P
    Health Policy; 1993 May; 24(2):145-53. PubMed ID: 10128800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A model-based cost-effectiveness analysis of osteoporosis screening and treatment strategy for postmenopausal Japanese women.
    Yoshimura M; Moriwaki K; Noto S; Takiguchi T
    Osteoporos Int; 2017 Feb; 28(2):643-652. PubMed ID: 27743068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation on the cost-effective threshold of osteoporosis treatment on elderly women in China using discrete event simulation model.
    Ni W; Jiang Y
    Osteoporos Int; 2017 Feb; 28(2):529-538. PubMed ID: 27581955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality of life in the economic evaluation of osteoporosis prevention and treatment.
    Tosteson AN
    Spine (Phila Pa 1976); 1997 Dec; 22(24 Suppl):58S-62S. PubMed ID: 9431646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Bone-specific treatment design in the treatment of postmenopausal osteoporosis. Pharmaco-economic aspects].
    Reginster JY; Ben Sedrine W; Gosset C
    Rev Med Liege; 1998 May; 53(5):290-3. PubMed ID: 9689885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The distribution problem in economic evaluation: income and the valuation of costs and consequences of health care programmes.
    Donaldson C; Birch S; Gafni A
    Health Econ; 2002 Jan; 11(1):55-70. PubMed ID: 11788982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A note on the depreciation of the societal perspective in economic evaluation of health care.
    Johannesson M
    Health Policy; 1995 Jul; 33(1):59-66. PubMed ID: 10143700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methods for systematic reviews of economic evaluations for the Guide to Community Preventive Services. Task Force on Community Preventive Services.
    Carande-Kulis VG; Maciosek MV; Briss PA; Teutsch SM; Zaza S; Truman BI; Messonnier ML; Pappaioanou M; Harris JR; Fielding J
    Am J Prev Med; 2000 Jan; 18(1 Suppl):75-91. PubMed ID: 10806980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France.
    Hiligsmann M; Reginster JY
    Osteoporos Int; 2019 Mar; 30(3):649-658. PubMed ID: 30701342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A health economic simulation model for the clinical management of osteoporosis.
    Jonsson E; Hansson-Hedblom A; Ljunggren Ö; Åkesson K; Spångeus A; Kanis JA; Borgström F
    Osteoporos Int; 2018 Mar; 29(3):545-555. PubMed ID: 29196775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost effectiveness/utility analyses. Do current decision rules lead us to where we want to be?
    Birch S; Gafni A
    J Health Econ; 1992 Oct; 11(3):279-96. PubMed ID: 10122540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting: based on the results of the SOTI and TROPOS trials.
    Borgström F; Jönsson B; Ström O; Kanis JA
    Osteoporos Int; 2006 Dec; 17(12):1781-93. PubMed ID: 17009083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implications of basing health-care resource allocations on cost-utility analysis in the presence of externalities.
    Labelle RJ; Hurley JE
    J Health Econ; 1992 Oct; 11(3):259-77. PubMed ID: 10122539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The concept of cost in the economic evaluation of health care. A theoretical inquiry.
    Johannesson M
    Int J Technol Assess Health Care; 1994; 10(4):675-82. PubMed ID: 7843887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Models for assessing the cost-effectiveness of the treatment and prevention of osteoporosis.
    Zethraeus N; Ben Sedrine W; Caulin F; Corcaud S; Gathon HJ; Haim M; Johnell O; Jönsson B; Kanis JA; Tsouderos Y; Reginster JY
    Osteoporos Int; 2002 Nov; 13(11):841-57. PubMed ID: 12415431
    [No Abstract]   [Full Text] [Related]  

  • 20. Cost-effectiveness of denosumab versus oral alendronate for elderly osteoporotic women in Japan.
    Mori T; Crandall CJ; Ganz DA
    Osteoporos Int; 2017 May; 28(5):1733-1744. PubMed ID: 28210776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.